•The Good Signal
Stanford’s 37,000 AI agents designed a cancer drug
On 17 September 2026 Science published Stanford’s Virtual Biotech: more than 37,000 AI agents curated 55,984 trials and found cell-type-specific targets were 40% more likely to clear Phase I–II, 48% more likely to reach market, and linked to 32% fewer adverse events — then proposed a B7-H3 antibody–drug conjugate for lung cancer. Computational strategy, not a Stanford FDA approval.